FDA schedules panel meeting on AquaBounty's biotech salmon

08/25/2010 | Los Angeles Times (tiered subscription model)

The FDA's Veterinary Medicine Advisory Committee will hold a meeting on Sept. 19 and 20 to evaluate scientific data and determine whether AquaBounty Technologies' biotech salmon should be approved for human consumption. The FDA also scheduled a public meeting for Sept. 21 to determine whether to label the product as being genetically modified.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ